

Pembrolizumab KEYNOTE-24

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Less serious and disabling adverse effects observed



Other adjustments



Long-term plateau in the survival



Pembrolizumab KEYNOTE-24

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: First line treatment of mNSCLC with tumour PD-L1 expression $\geq 50\%$ TPS with no EGFR or ALK positive tumour mutations

Experimental Arm: Pembrolizumab

Control Arm: Platinum-based chemotherapy



